

CLAIMS

1. A side effect-relieving agent for thiazolidine compounds which comprises a crude drug as an active
5 ingredient comprising Ephedrae Herba, Glycyrrhizae Radix and Gypsum Fibrosum each of which is in a form of ground powders, extracts or mixtures of powders and extracts.
2. The side effect-relieving agent according to
10 Claim 1, comprising the crude drug in a form of a crude drug preparation.
3. The side effect-relieving agent according to
15 Claim 2, wherein the crude drug preparation is selected from Bofu-tsusho-san, Goko-to, Makyo-kanseki-to and Eppika-jutsu-to.
4. The side effect-relieving agent according to
20 Claim 1, wherein the thiazolidine compound is selected from pioglitazone, troglitazone, rosiglitazone and pharmaceutically acceptable salts thereof.
5. The side effect-relieving agent according to
25 Claim 1, wherein the Glycyrrhizae Radix is formulated in an amount of 0.1 to 3 parts by weight and Gypsum Fibrosum is formulated in an amount of 0.5 to 5 parts by weight on the basis of 1 part by weight of Ephedrae Herba.
6. The side effect-relieving agent according to
30 Claim 1, wherein the crude drug is coated with a coating agent or the crude drug is dispersed in a base to make a matrix form.
7. The side effect-relieving agent according to
35 Claim 1, which further contains conventional pharmaceutically acceptable additives.

8. A pharmaceutical formulation, which contains the side effect-relieving agent according to Claim 1 together with a thiazolidine compound.

5

9. A method of treating the side effect-relieving agent according to Claim 1 for relieving a side effect induced by a thiazolidine compound.

10

10. The method according to Claim 9, wherein the side effect-relieving agent according to Claim 1 is used orally in a diabetic concomitantly with, or before or after administration of a thiazolidine compound.

15

11. A hypoglycemic effect enhancer for thiazolidine compounds which comprises a crude drug as an active ingredient comprising Ephedrae Herba, Glycyrrhizae Radix and Gypsum Fibrosum each of which is in a form of ground powders, extracts or mixtures of powders and extracts.

20

12. The hypoglycemic effect enhancer according to Claim 11, comprising the crude drug in a form of a crude drug preparation.

25

13. The hypoglycemic effect enhancer according to Claim 12, wherein the crude drug preparation is selected from Bofu-tsusho-san, Goko-to, Makyo-kanseki-to and Eppika-jutsu-to.

30

14. The hypoglycemic effect enhancer according to Claim 11, wherein the thiazolidine compound is selected from pioglitazone, troglitazone, rosiglitazone and pharmaceutically acceptable salts thereof.

35

15. The hypoglycemic effect enhancer according to Claim 11, wherein the Glycyrrhizae Radix is formulated in

an amount of 0.1 to 3 parts by weight and Gypsum Fibrosum is formulated in an amount of 0.5 to 5 parts by weight on the basis of 1 part by weight of Ephedrae Herba.

5 16. The hypoglycemic effect enhancer according to Claim 11, which further contains conventional pharmaceutically acceptable additives.

10 17. The hypoglycemic effect enhancer according to Claim 11, wherein the crude drug is coated with a coating agent or the crude drug is dispersed in a base to make a matrix form.

15 18. A pharmaceutical formulation, which contains the hypoglycemic effect enhancer according to Claim 11 together with a thiazolidine compound.

20 19. A method of treating the hypoglycemic effect enhancer according to Claim 11 for enhancing a hypoglycemic effects of a thiazolidine compound.

25 20. The method according to Claim 19, wherein the hypoglycemic effect enhancer according to Claim 11 is used orally in a diabetic concomitantly with, or before or after administration of a thiazolidine compound.